Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Toyota Motor Corp (TM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Toyota Motor Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Toyota Motor Corp trades at $174.77 (market cap $206.62B). The key difference: Toyota Motor Corp is far larger — about 5.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Toyota Motor Corp pays a 3.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TM | |
|---|---|---|
Market Cap | $39.89B | $206.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $248.29 |
52-Week Low | $278.09 | $166.50 |
Enterprise Value | $38.15B | $370.82B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Toyota Motor (TM) trades at $176.45, up 1.22% today, with a neutral technical signal and strong fundamentals including a P/E of 9.67 and three consecutive quarterly EPS beats. The company announced a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling strategic U.S. investment. Revenue grew to $48.04T in 2025, though net income dipped slightly to $4.77T, while cash flow trends show projected recovery in 2026.
TM presents a value opportunity with low valuation multiples and consistent profitability, but faces risks from competitive pressures and fluctuating margins. Analyst consensus is mixed with 37.5% buy ratings, reflecting cautious optimism amid hybrid vehicle strength and macroeconomic uncertainties. The stock's outlook hinges on execution of expansion plans and sustained demand for fuel-efficient models.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
